To include your compound in the COVID-19 Resource Center, submit it here.
Interim data from 21 evaluable elderly patients with newly diagnosed AML in an ongoing, open-label, U.S. Phase I/II trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury